Zur Kurzanzeige

dc.contributor.authorAlonso Sardón, Montserrat 
dc.contributor.authorSáez Lorenzo, María
dc.contributor.authorChamorro Fernández, Antonio Javier 
dc.contributor.authorFernández Martín, Celia Luz 
dc.contributor.authorIglesias de Sena, Helena 
dc.contributor.authorGonzález Núñez, Verónica 
dc.contributor.authorSantos Sánchez, José Ángel 
dc.contributor.authorCarbonell Muñoz, Cristina 
dc.contributor.authorLorenzo Gómez, María Fernanda 
dc.contributor.authorMirón Canelo, José Antonio 
dc.date.accessioned2026-01-21T11:37:42Z
dc.date.available2026-01-21T11:37:42Z
dc.date.issued2022
dc.identifier.citationAlonso-Sardón, M., Sáez-Lorenzo, M., Chamorro, A. J., Fernández-Martín, L. C., Iglesias-de-Sena, H., González-Núñez, V., Santos-Sánchez, J. Á., Carbonell, C., Lorenzo-Gómez, M. F., & Mirón-Canelo, J. A. (2022). Adverse Effects in Patients with Intellectual and Developmental Disabilities Hospitalized at the University Clinical Hospital. Journal of Personalized Medicine, 12(11). https://doi.org/10.3390/JPM12111898es_ES
dc.identifier.urihttp://hdl.handle.net/10366/169122
dc.description.abstract[EN] Background: Providing the patient with the health care they need in a personalized and appropriate manner and without adverse effects (AEs) is a part of quality of care and patient safety. The aim of this applied research project was the assessment of AEs as a clinical risk in patients with high social vulnerability such as persons with intellectual and developmental disabilities (PwIDD). (2) Methods: A retrospective epidemiological cohort study was performed on exposed and unexposed groups (the control group) in order to estimate the incidence of AEs in PwIDDs and assess their importance for this category of patients. (3) Results: AEs were observed with a frequency of 30.4% (95% CI) in the PwIDD exposed group, with significant differences to the unexposed group (p = 0.009). No differences were observed with regards to gender. Age was as a marker of care risk, with the highest incidence of AEs in the group of 60–69 years. (4) Conclusions: PwIDDs have a high risk of suffering AEs while receiving health care assistance due to their high social and clinical vulnerability. Health care practitioners must therefore be aware of these results and keep these observations in mind in order to carry out personalized, preventive, competent, effective, and safe medical care.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCare qualityes_ES
dc.subjectPatient safetyes_ES
dc.subjectAdverse effectses_ES
dc.subjectPersons with intellectual and developmental disabilitieses_ES
dc.subject.meshDisability Evaluation *
dc.subject.meshIntellectual Disability *
dc.subject.meshHealth Care Quality, Access, and Evaluation *
dc.titleAdverse effects in patients with intellectual and developmental disabilities hospitalized at the University Clinical Hospitales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.3390/jpm12111898es_ES
dc.identifier.doi10.3390/JPM12111898
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.essn2075-4426
dc.journal.titleJournal of Personalized Medicinees_ES
dc.volume.number12es_ES
dc.issue.number11es_ES
dc.page.initial1898es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsdiscapacidad intelectual *
dc.subject.decscalidad, acceso y evaluación de la atención de salud *
dc.subject.decsvaloración de discapacidades *


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NonCommercial-NoDerivatives 4.0 Internacional